US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Vator Securities Sole Bookrunner in Nanoform SEK 71 million private placement, Borenius legal advisor in joint Swedish-Finnish operation

The private placement was directed to Swedish and Finnish, HNWI, family offices and institutional investors where Mandatum Life Insurance Company (Sampo Group) acted as anchor investor.Every year only 30-60 drugs are approved by regulatory authorities. Failures in trials cost €50bn. Nanoform can give failed drug molecules a second chance by providing ground breaking services in nanotechnology and drug particle engineering for the international pharma industry. Nanoform’s proprietary technology, Controlled Expansion of Supercritical Solutions (CESS) is a tested and proven method whereby

Vator Securities Sole Bookrunner in SEK 324 million direct share issue - the largest in Swedish history in a diagnostics company

Vator Securities Sole Bookrunner in successful SEK 324 million direct share issue in Immunovia, the largest ever in a diagnostics company in Sweden.Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. The Share Issue generated strong demand from reputable institutions in Sweden and internationally, such as Swedbank Robur, Handelsbanken Fonder, Alfred Berg

Vator Securities acted as Sole Bookrunner and Advisor in connection with Ascelia Pharmas Pre-IPO share issue

Vator Securities acted as Sole Bookrunner and Advisor in connection with the transaction raising SEK 60 million.Ascelia Pharma is a Swedish-based specialty oncology drug development company with a late stage pipeline of products with potential to significantly improve survival in cancer patients. The lead asset Mangoral® is a novel MR imaging (MRI) drug, which is being developed for detection of liver metastases in patients with severely impaired kidney function who are at risk of serious side effects if given any of the current imaging drugs on the market. Today, these patients have no

Vator Securities appoints Lars Hevreng as Head of Research

Vator Securities announced today that Lars Hevreng has been appointed as Head of Research and Senior Equity Partner with the firm. Prior to joining Vator Securities, Hevreng served as a top ranked healthcare analyst at major financial institutions such as SEB and most recently Danske Bank.Hevreng is one of Sweden’s highest ranked healthcare analysts, covering companies such as AstraZeneca, Sobi and Elekta. He has also covered Recipharm, Lifco and recently Medicover, when these companies went public. The position as Head of Research at Vator Securities implies that Hevreng will lead the

There are no items matching the current filter
There are no more items matching the current filter
Back to top